Clinical trialPhase 2Completed
Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients
An Open Non-randomized Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Tarceva in Combination With Capecitabine in Patients With Advanced Pancreatic Cancer
- Outcome
- Finished, no results posted
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- March 2008
- Expected end
- August 2010
- Enrollment
- 32 participants
- Sites
- 8
- Primary outcomes
- Objective response rate following RECIST criteria
- Sponsor
- Other
- Results posted
- No
- Last update
- 18 August 2010
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to determine efficacy of the treatment with erlotinib in combination with capecitabine in patients with advanced pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
This efficacy will be determined by objective response rate following RECIST criteria.
Papers 1
- Registry-listed results paperPhase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study). PMID 23393373↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.